Maze Therapeutics (MAZE) Receivables - Other (2025 - 2026)
Maze Therapeutics' (MAZE) quarterly Receivables - Other came in at $1.8 million in Q1 2026, up 20.0% quarter-over-quarter from $1.5 million in Q4 2025.
Maze Therapeutics (MAZE) Receivables - Other (2025 - 2026) Analysis & Trends
Maze Therapeutics has disclosed Receivables - Other across 2 years of filings, most recently posting $1.8 million for Q1 2026.
- Receivables - Other for Q1 2026 came in at $1.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (changed N/A YoY), and the FY2025 annual result was $1.5 million, changed N/A from the prior year.
- Receivables - Other came in at $1.8 million for Q1 2026 at Maze Therapeutics, up from $1.5 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.8 million in Q1 2026 to a low of $700000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Maze Therapeutics | 1.31 Bn | 1.31 Bn | 18.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.80 Mn |
| Mar 31, 2026 | 1.80 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 700,000.00 |
| Sep 30, 2025 | 700,000.00 |